CCL20 Antibody

What is CCL20 and what are its primary functions in biological systems?

CCL20, also known as LARC, MIP-3-alpha, or C-C motif chemokine 20, is a small protein (approximately 10.8 kilodaltons) belonging to the C-C chemokine family. It is primarily expressed in lymphatic tissue, lung, and liver, and is produced by cells involved in inflammatory and immune responses . CCL20 functions as a chemoattractant for lymphocytes, particularly those expressing the CCR6 receptor.

What types of CCL20 antibodies are available for research applications?

Research-grade CCL20 antibodies come in several formats to accommodate different experimental needs:

A wide range of CCL20 antibodies is commercially available from multiple suppliers, with varied applications including Western Blot (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FCM), and Immunofluorescence (IF) . Specialized antibodies like the humanized IgG1κ antibody GSK3050002 have been developed specifically for neutralization studies with high binding affinity (48 pM) to human CCL20 .

How can I select the appropriate CCL20 antibody for my specific research question?

Selecting the appropriate CCL20 antibody depends on several experimental factors:

• Experimental technique: Different applications require antibodies validated for that specific technique. For instance, antibodies for Western blotting should recognize denatured epitopes, while those for immunoprecipitation should recognize native epitopes.

• Species reactivity: Ensure the antibody recognizes CCL20 in your experimental species. While many antibodies react with human CCL20, fewer cross-react with mouse or rat orthologs .

• Clonality considerations: Monoclonal antibodies offer high specificity for a single epitope, making them excellent for applications requiring consistency. Polyclonal antibodies recognize multiple epitopes and may provide stronger signals for certain applications.

• Application-specific requirements: For sandwich ELISA, paired antibodies recognizing different epitopes are required. For example, Mouse anti Human CCL20 antibody clone O03-3H12 can be used as a detection antibody in conjunction with clone J03-4D4 as a capture antibody .

What are the optimal conditions for using CCL20 antibodies in different experimental assays?

Optimizing conditions for CCL20 antibody-based assays requires consideration of several parameters:

For Western Blot analysis:

• Sample preparation: Effective protein extraction using appropriate lysis buffers

• Blocking conditions: Typically 5% non-fat milk or BSA in TBST

• Antibody dilution: Usually between 1:500-1:2000 depending on the specific antibody

• Incubation time: Primary antibody incubation overnight at 4°C often yields best results

• Detection method: Selection between chemiluminescence, fluorescence, or colorimetric detection based on sensitivity requirements

For Flow Cytometry:

• Cell fixation/permeabilization: Required for intracellular CCL20 detection

• Antibody concentration: Titration recommended to determine optimal signal-to-noise ratio

• Controls: Isotype controls and FMO (Fluorescence Minus One) controls essential for accurate gating

For Immunohistochemistry:

• Antigen retrieval method: Heat-induced epitope retrieval in citrate buffer (pH 6.0) often effective

• Detection system: Selection between avidin-biotin, polymer-based, or tyramide signal amplification based on sensitivity requirements

Each assay requires optimization steps to ensure reliable and reproducible results when working with CCL20 antibodies.

How can I validate the specificity of CCL20 antibodies in my experimental system?

Validating antibody specificity is crucial for ensuring experimental rigor. The following approaches are recommended for CCL20 antibody validation:

• Positive and negative controls: Include known CCL20-positive tissues/cells (e.g., activated dendritic cells) and CCL20-negative or knockout samples.

• Neutralization/competition assays: Pre-incubate the antibody with recombinant CCL20 protein before application to demonstrate signal reduction.

• Multiple antibody approach: Use antibodies from different clones recognizing different epitopes to confirm consistent detection patterns.

• RNA-protein correlation: Compare antibody-based protein detection with mRNA expression data from RT-PCR or RNA sequencing.

• Knockout/knockdown validation: Use CRISPR/Cas9 or siRNA approaches to eliminate or reduce CCL20 expression and confirm corresponding loss of antibody signal.

• Mass spectrometry validation: For immunoprecipitation experiments, confirm pulled-down proteins by mass spectrometry analysis.

These complementary approaches collectively strengthen confidence in antibody specificity and experimental results.

What experimental models can be used to study CCL20-CCR6 interactions using CCL20 antibodies?

Several experimental models have been developed to study CCL20-CCR6 interactions:

• Skin suction blister model: This human experimental model was employed in the GSK3050002 clinical study to assess target engagement and ability of the neutralizing antibody to inhibit recruitment of inflammatory CCR6-expressing cells . This model provides valuable insights into the in vivo effects of CCL20 neutralization.

• Chemotaxis assays: In vitro migration assays using CCR6-expressing cells (such as Th17 cells or immature dendritic cells) can measure the chemotactic response to CCL20 and its inhibition by neutralizing antibodies.

• Inflammatory disease models: Various mouse models of inflammatory conditions (such as experimental autoimmune encephalomyelitis, colitis, or arthritis) can be used to study the role of CCL20-CCR6 axis and the effects of its modulation using neutralizing antibodies.

• Cell-based receptor binding assays: These assays measure the binding of labeled CCL20 to CCR6-expressing cells and can assess competitive inhibition by neutralizing antibodies.

• Ex vivo tissue culture systems: Tissue explants from human or animal sources can be cultured and treated with CCL20 antibodies to study effects on CCL20-dependent inflammatory responses in a more physiologically relevant context than cell lines.

How are neutralizing CCL20 antibodies being developed for therapeutic applications?

The development of neutralizing CCL20 antibodies as potential therapeutics has gained significant attention due to the role of CCL20 in various inflammatory and autoimmune conditions. The development pathway typically includes:

• Antibody engineering and optimization: Humanized antibodies like GSK3050002 are engineered to maximize binding affinity while minimizing immunogenicity. This particular antibody has demonstrated high binding affinity (48 pM) to human CCL20 .

• First-in-human studies: Clinical trials such as the one conducted with GSK3050002 evaluate safety, pharmacokinetics, and pharmacodynamics of the antibody. This randomized, double-blind, placebo-controlled study in healthy volunteers represents an essential step in therapeutic development .

• Target engagement assessment: Specialized models, such as the skin suction blister model, are employed to confirm that the antibody effectively engages with CCL20 and inhibits recruitment of CCR6-expressing inflammatory cells in vivo .

• Disease-specific efficacy studies: Following initial safety studies, antibodies are tested in patients with specific inflammatory or autoimmune conditions where CCL20 plays a pathogenic role.

The therapeutic development of anti-CCL20 antibodies represents a promising approach for conditions where CCL20-mediated recruitment of inflammatory cells contributes to disease pathology.

What role does CCL20 play in inflammatory and autoimmune disease pathogenesis?

CCL20 has been implicated in numerous inflammatory and autoimmune conditions through its ability to recruit CCR6-expressing cells:

CCL20 is particularly involved in the pathogenesis of chronic inflammatory disorders, specifically interstitial lung fibrosis and chronic obstructive pulmonary disease (COPD) . Additionally, research has indicated that CCL20 can contribute to tumor metastasis, suggesting potential oncological applications for CCL20-targeting therapeutics .

The connection between CCL20 and these conditions has led researchers to propose that inhibition of CCL20, along with its receptor CCR6, might have valuable therapeutic potential for treatment of autoimmune and inflammatory diseases .

What considerations are important when designing experiments to investigate CCL20 neutralization in disease models?

When designing experiments to investigate CCL20 neutralization in disease models, researchers should consider:

• Timing of intervention: Determining whether to administer CCL20 antibodies prophylactically (before disease onset) or therapeutically (after disease establishment) significantly impacts experimental design and interpretation of results.

• Dose-response relationship: Establishing the dose-response relationship is critical, as insufficient dosing may lead to false-negative results while excessive dosing may cause off-target effects.

• Route of administration: Depending on the disease model, different routes (intravenous, intraperitoneal, subcutaneous, or local administration) may be more appropriate.

• Control antibodies: Proper isotype controls are essential to distinguish specific effects of CCL20 neutralization from non-specific antibody effects.

• Biomarkers of target engagement: Including assays to confirm target engagement (e.g., measuring free CCL20 levels or CCR6+ cell infiltration) helps validate the mechanism of action.

• Combined inhibition strategies: Considering the redundancy in chemokine networks, combination approaches targeting multiple chemokines or their receptors may be necessary to achieve significant therapeutic effects.

• Translational relevance: Using human samples or humanized models when possible increases the translational potential of findings.

What are the best practices for quantifying CCL20 in biological samples?

Accurate quantification of CCL20 in biological samples requires careful consideration of sampling, processing, and analytical techniques:

• ELISA-based quantification: Sandwich ELISA represents the gold standard for CCL20 quantification in serum, plasma, or cell culture supernatants. For optimal results, paired antibodies such as Mouse anti Human CCL20 antibody clone J03-4D4 as capture antibody and biotinylated clone O03-3H12 as detection antibody can be employed .

• Sample collection and processing:

  • Standardize collection times due to potential diurnal variation

  • Process samples promptly to prevent protein degradation

  • Consider protease inhibitors to preserve chemokine integrity

  • Use consistent freeze-thaw protocols as repeated cycles can degrade proteins

• Multiplex assays: Luminex or similar bead-based multiplex assays allow simultaneous quantification of CCL20 alongside other cytokines/chemokines, providing contextual information about the inflammatory milieu.

• Mass spectrometry: For complex samples or when antibody cross-reactivity is a concern, targeted mass spectrometry approaches offer high specificity.

• Reference standards: Include recombinant CCL20 standards with known concentrations to generate reliable standard curves.

• Internal controls: Incorporate internal quality controls across multiple plates/runs to minimize inter-assay variability.

• Data normalization: Consider normalizing CCL20 levels to total protein content or other relevant parameters depending on the sample type.

How can I design experiments to distinguish between direct and indirect effects of CCL20 neutralization?

Distinguishing between direct and indirect effects of CCL20 neutralization requires sophisticated experimental approaches:

• In vitro versus in vivo studies: Compare effects in simplified in vitro systems (where indirect effects are minimized) with more complex in vivo models.

• Time-course experiments: Map the temporal sequence of events following CCL20 neutralization to identify primary (early) versus secondary (late) effects.

• Cell-specific responses: Isolate different cell populations after antibody treatment to determine which cells are directly affected by CCL20 neutralization.

• Conditional knockout approaches: Use cell-type specific CCR6 knockout models to determine which cell populations mediate CCL20 effects in vivo.

• Ex vivo functional assays: Perform functional assays on cells isolated from antibody-treated animals to assess direct effects on cellular function.

• Transcriptomics and proteomics: Employ genome-wide expression profiling to identify immediate-early gene responses versus secondary transcriptional programs activated following CCL20 neutralization.

• Pathway inhibition studies: Combine CCL20 neutralization with inhibitors of suspected downstream pathways to determine the mechanism of observed effects.

• Adoptive transfer experiments: Transfer CCR6+ versus CCR6- cells into recipient animals to identify which cell populations mediate observed in vivo effects.

What are the emerging technologies for studying CCL20-CCR6 interactions at the molecular level?

Several cutting-edge technologies are advancing our understanding of CCL20-CCR6 interactions:

• Cryo-electron microscopy: Enables visualization of CCL20-CCR6 complexes at near-atomic resolution, providing insights into binding mechanisms and conformational changes.

• CRISPR/Cas9 genome editing: Allows precise modification of CCL20 or CCR6 genes to study structure-function relationships in endogenous contexts.

• Single-cell RNA sequencing: Provides high-resolution analysis of CCR6+ cell populations and their responses to CCL20 stimulation or neutralization.

• Intravital microscopy: Enables real-time visualization of CCR6+ cell trafficking in response to CCL20 gradients in living organisms.

• Bioluminescence resonance energy transfer (BRET): Allows real-time monitoring of CCL20-CCR6 interactions and downstream signaling events in living cells.

• Chemokine receptor reporter systems: Engineered cell lines expressing fluorescent or luminescent reporters downstream of CCR6 activation provide sensitive readouts of receptor function.

• Advanced proteomics: Techniques such as proximity labeling proteomics identify proteins associated with activated CCR6 receptors, uncovering previously unknown signaling components.

• Organ-on-chip technologies: Microfluidic systems recreating tissue microenvironments enable study of chemokine gradients and cell migration in physiologically relevant contexts.